Aerosol Biology Small Animal Models

气溶胶生物学/小动物模型核心，以下称为ABSAM核心或核心，将提供支持 对于天花和肺鼠疫的研究，因为这些疾病将是NIAID A类研究最深入的 其他体内病原体模型将在明智地选择顾问的情况下开发，并作为 尽管核心将能够通过全面的接种途径感染动物，但需求出现了 为呼吸道感染途径的使用提供特殊支持。呼吸道是猪瘟病毒的感染途径。 人类的大多数病原体，很可能成为生物武器的攻击目标；然而，S的信息却很匮乏 在描述NIAID A、B和C类药物分子发病机制的科学文献中 呼吸道感染，以及对这种感染的先天和粘膜反应。 研究病原体与呼吸道的相互作用的起点是可重复和有效的 模拟自然感染的方法。核心将拥有通过鼻腔感染动物的专业知识， 气管内接种和气雾剂暴露的接种途径。核心的一个主要重点将是为 允许输送的具有大范围平均空气动力学颗粒尺寸的气溶胶的产生和量化 细菌和病毒传播到呼吸道的不同区域。现有和定制设计的仪器 将用于支持气溶胶感染后发病机制的基本问题的研究，并开发出特定的 NIAID A、B和C类药物的治疗和预防药物临床前试验的挑战模型。这个 CORE将有能力将治疗药物雾化并输送到呼吸道，用于早期研究 干预战略，并将开发和测试仪器，旨在灭活空气中的生物粒子。 其他核心服务将包括：动物收购、检疫和驯化、健康监测、畜牧业、 标本采集、外科服务、临床实验室样本分析、病理学服务和报告撰写。 该中心将支持第7区、RCE网络中其他中心的研究，以及那些来自合格的 生物技术公司。小型生物技术公司可能会发现这个核心特别有吸引力，因为他们很可能 缺乏BSL-3设施，以及在生物医学研究中使用动物所需的监管监督(AAALAC，USDA， 和小灵通)。此外，这些公司通常缺乏进行体内感染的专业知识，无法为动物提供 对受感染的动物进行饲养，并进行必要的技术以获取用于确定 实验终点。

The Aerosol Biology/Small Animal Models Core, hereafter referred to as the ABSAM Core or Core, will provide support for smallpox and pneumonic plague research as these diseases will be the most intensely studied NIAID Category A agents in Region 7. Other in vivo pathogen models wil be developed with the judicious selection of consultants, and as the needs arise Although the Core will be capable of infecting animals through a full range of inoculation routes, it will provide exceptional support for the use of respiratory routes of infection. The respiratory tract is the route of infection of the majority of human pathogens and will likely be the target of bioweapons; however, there _s a paucity of information in the scientific literature describing the molecular pathogenesis of NIAID category A, B, and C agents following respiratory tract infections, and the innate and mucosal responses to such infections. The starting point for the study of interactions of pathogens with the respiratory tract is a reproducible and efficient method for mimicking the natural infection. The Core will have expertise to infect animals by the intranasal, intratracheal, and aerosol exposure routes of inoculation. A major focus of the Core will be to provide support for the generation and quantification of aerosols with a wide range of mean aerodynamic particle sizes permitting the delivery of both bacteria and viruses to distinct regions of the respiratory tract. Existing and custom designed instrumentation will be used to support the study of basic questions in pathogenesis following aerosol infection, and to develop specific challenge models for preclinical testing of therapeutics and prophylactics for NIAID category A, B. and C agents. The Core will have the capacity to aerosolize and deliver therapeutics to the respiratory tract for the study of early intervention strategies, and wilt develop and test instrumentation designed to inactivate bioparticles in the air. Additional Core services will include: animal acquisition, quarantine and acclimation, health surveillance, husbandry, specimen collection, surgical services, clinical laboratory sample analysis, pathology services, and report writing. The Core will support studies in Region 7, at other Centers in the RCE network, and those originating from qualified biotechnology companies. Small biotechnology companies may find this Core particularly attractive as they will likely lack BSL-3 facilities, and the required regulatory oversight for using animals in biomedical research (AAALAC, USDA, and PHS). In addition, these companies will typically lack the expertise to carry out in vivo infections, to provide animal husbandry for infected animals, and to perform techniques necessary to acquire specimens for determination of experimental end-points.